GE HealthCare has introduced LOGIQ Focus, a general imaging ultrasound system combining cSound Architecture with automated scanning and workflow tools. In a third-party abdominal imaging study, the system completed scans 26% faster than a comparator, while 90% of participating physicians rated image quality highly.
Masimo has received FDA 510(k) clearance for atrial fibrillation detection on its Radius VSM monitor, reporting 97% sensitivity and 100% specificity in clinical validation. The feature joins an earlier-cleared respiratory depression algorithm, extending pulse oximetry into automated recognition of clinically important physiological patterns.
Most FDA-cleared surgical robots still operate under direct human control, while research systems are beginning to automate individual tasks. Moving from task automation to independent surgery requires solving perception, tissue variability, failure recovery and liability.
Pathology foundation models learn reusable representations from millions of tissue images and can be adapted for cancer detection, biomarkers and prognosis, potentially replacing one-algorithm-per-task development.
Invenio Imaging completes ON-SITE enrolment as NIO Lung Cancer Reveal moves toward pivotal analysis and a potential FDA submission.
Bausch + Lomb’s Orphia brings AI to cataract education, but adoption will depend on workflow integration, validation, privacy and trust.
iHealthScreen Inc. has received U.S. Food and Drug Administration 510(k) clearance for iPredict-DR, an AI-powered Software as a Medical Device for automated diabetic retinopathy screening. The retinal imaging software detects more than mild diabetic retinopathy in adults with diabetes who have not previously been diagnosed with the condition, placing the healthcare AI developer into a
Royal Philips’ Alturion ultrasound launch targets AI-powered imaging workflows as hospitals face rising scan volumes and staffing pressure.
Discover how Vilo Signal OS plans to turn smart ring data into proactive health guidance, and why validation, privacy and trust will decide its future.
Discover how Greenstone Biosciences and Intel plan to scale iPSC drug discovery, and why validation will determine the platform’s impact.